TOGA is thrilled by this commitment. As the peak body for lung cancer research in Australia and New Zealand, we understand the transformative power of research funding. As Dr Megan Sanders, TOGA’s Executive Officer, points out “Investment in research has the power to change cancer from a terminal illness to a manageable chronic illness.”
Increased Funding for Lung Cancer Research
The ‘Health Research for a Future Made in Australia’ package will include $1.4 billion for new research via the Medical Research Future Fund (MRFF). This package will include a focus on a 10-Year Low Survival Cancers Mission and will directly address key areas that will benefit TOGA members and their crucial work.
Historically, lung cancer research has been underfunded despite claiming the most lives of all tumour types. This investment pledges more resources towards this critical area, bringing us closer to effective treatments and ultimately saving lives.
Dr Sanders reiterates that “less than 6% of cancer research funding has been allocated to lung cancer and mesothelioma research, despite lung cancer claiming the most lives of all tumour types. This investment in research, particularly clinical trials, will maximise the benefit, quality, and cost-effectiveness of new treatments and enhance survivorship and supportive care.”
